ImmuneBridge

ImmuneBridge, founded in 2018, is a pioneering biotechnology company focused on developing allogeneic immunotherapies for cancer, with its headquarters in the United States. The company's innovative approach lies in its use of cord blood-derived immune stem cells, offering a consistent and abundant source for cellular immunotherapies. ImmuneBridge's core technology significantly expands these stem cells without losing their immune multipotency, targeting both hematological malignancies and solid tumors.

Within the platform, ImmuneBridge leverages a proprietary technology that includes a novel small molecule capable of expanding cord blood HSPCs over 100,000-fold. The focus is currently on natural killer (NK) cell products for treating hematological malignancies, with future plans to address solid tumors by utilizing the unique cellular advantages.

The company last raised a $12.00M Seed Round investment in January 2023, attracting notable investors such as Gaingels, One Way Ventures, Insight Partners, and MERL Ventures Fund. The capital infusion aims to validate the clinical and economic benefits of their platform as they move towards clinical trials. With a focus on reducing discovery and manufacturing costs, ImmuneBridge offers substantial potential for scalable, commercially viable cellular immunotherapy solutions.